Glaucoma Treatment
Glaucoma Treatment
Every treatment for glaucoma works the same way: it lowers the pressure inside the eye so that the remaining optic nerve fibres are no longer being damaged. What differs is the route — drops that reduce fluid production or improve its outflow, laser treatment that opens the drainage pathway or the angle itself, and surgery that creates a new route for fluid to leave. None of them brings back nerve fibres that have been lost, and none restores a field of vision that has gone. This is worth stating plainly because it sets the expectation correctly: treatment is a way of holding a position, and the position that is held depends on how much has already been lost. Choosing between the options is a matter of the type of glaucoma — open or closed angle — the target pressure that needs to be reached, how quickly the nerve appears to be losing ground, the state of the other eye, and what suits the person taking the treatment every day for the rest of their life.
The target, not a cure: what treatment is actually for
The most useful way to think about glaucoma treatment is as a pressure target rather than a treatment of the disease itself:
- A target pressure is chosen for each eye, set lower than the pressure at which damage occurred and lower again where damage is advanced or progressing quickly. It is a working figure, revised as the tests accumulate.
- Reaching the target is the measure of success, not the disappearance of a disease. Since open-angle glaucoma has no symptoms, a person who feels entirely well may still need their treatment adjusted.
- Already-lost nerve fibres and field do not return. No drop, laser or operation restores them, which is why the value of treatment is concentrated on the future rather than the past.
- A stable field is the treatment working, not a reason to stop. Pressure tends to return to its previous level when drops are left off, and the loss that follows is silent.
What this means for the conversation with a doctor. Two questions are worth asking at the outset: how much damage is there now, and what is the pressure target for this eye. With those two answers, a treatment plan becomes something that can be followed and assessed rather than simply accepted.
Eye drops: usually the first line, and always the daily one
Drops are the commonest treatment for open-angle glaucoma and the treatment most likely to be continued for decades, which makes the practical details as important as the pharmacology:
- Prostaglandin analogues are usually the first choice. They increase the outflow of fluid through the tissues at the back of the eye, are taken once daily in the evening, and tend to be the most effective single agent.
- Beta-blockers reduce the production of fluid inside the eye. They are taken twice daily, are widely used, and are avoided where there is asthma or a slow heart rate.
- Carbonic anhydrase inhibitors reduce fluid production and come both as drops and as tablets or injections. The oral and intravenous forms are reserved for bringing pressure down quickly.
- Alpha-agonists both reduce production and improve outflow, and are frequently used as an addition to a prostaglandin.
- Cholinergics improve outflow through the drainage pathway, and are also used to pull the iris away from a narrow angle.
The practical points that decide whether drops work. Technique matters — a drop that misses the eye or is washed away by blinking achieves nothing. Pressing gently on the inner corner after instilling reduces the amount that drains into the nose and is absorbed generally, which reduces side effects. Where more than one drop is used, an interval of several minutes between them prevents the second washing out the first. Side effects are common and manageable: redness and eyelash growth with prostaglandins, stinging, and a change in the appearance of the eye that is worth mentioning rather than enduring silently. Missing doses is the most frequent reason a pressure that was controlled stops being controlled, and the response should be to say so rather than to double up.
Laser treatment: a procedure in the clinic, not an operation
Laser treatment takes only minutes, is performed in the clinic without a general anaesthetic, and has become a genuine option earlier in the pathway than it once was:
- Selective laser trabeculoplasty applies brief pulses of light to the drainage meshwork to improve outflow through the eye’s own pathway. It can be used as a first treatment or added to drops, and where it works it often reduces the number of drops needed.
- Laser iridotomy makes a tiny opening in the iris so that fluid can reach the drainage angle where a narrow iris has been blocking it. It is the definitive treatment for angle closure, and it is applied to the other eye as well in most cases.
- Cyclophotocoagulation reduces fluid production by treating the tissue that makes it. It is reserved for eyes where other approaches have not achieved control or are unlikely to be suitable.
- Repeatability varies by procedure. A trabeculoplasty can be repeated in many eyes, whereas an iridotomy is a one-off opening. Knowing which is which matters when planning over decades.
What the day involves. A trabeculoplasty is performed at the slit lamp or with the patient seated at a laser, taking a few minutes, with pressure checked afterwards. An iridotomy is similarly brief. Both are followed by a short period of drops, and both are checked within weeks to see whether the intended reduction in pressure has been achieved.
Surgery: when drops and laser are not enough
Operations for glaucoma create a new route for fluid to leave the eye, and they are usually considered when the target pressure cannot be reached by other means:
- Trabeculectomy is the established operation. A small channel is created under the conjunctiva so that fluid can drain into a bleb beneath the eyelid, and it typically achieves a larger reduction in pressure than drops or laser alone.
- Drainage device surgery implants a small tube and plate to provide a controlled route for fluid. It is often chosen where the conjunctiva has been scarred by previous operations or inflammation, or where a trabeculectomy has not lasted.
- Minimally invasive glaucoma surgery, known collectively as MIGS, uses small implants or microscopic incisions through the eye’s internal drainage pathways. The reduction achieved is usually smaller than a trabeculectomy, but so is the disruption, and these procedures are frequently performed at the same time as cataract surgery.
- The choice depends on the eye, not only on the pressure. Previous surgery, inflammation, the state of the conjunctiva, how much field is left and how fast it is going are all weighed, and the operation is planned to fit the eye rather than the other way round.
What recovery involves. Glaucoma surgery requires follow-up that is more intensive than either drops or laser, particularly in the first weeks, when the drainage channel can heal too much or drain too fast. That follow-up is part of the treatment rather than an afterthought, and it is one of the reasons the operation is considered carefully rather than performed at the first sign of difficulty.
An acute angle-closure attack: treatment that cannot wait
An attack of acute angle closure is treated as an emergency, and the sequence is designed to bring the pressure down and open the angle within hours:
- Pressure is lowered medically and immediately, with drops and with a carbonic anhydrase inhibitor given by mouth or by injection, alongside agents that reduce the volume of fluid in the eye.
- The iris is pulled away from the angle with a cholinergic drop, which begins to reopen the drainage pathway while the other medication takes effect.
- A laser iridotomy is then performed to create a permanent opening in the iris, so that fluid can reach the angle even if the iris comes forward again.
- The other eye is treated preventively. It shares the same anatomy, and an attack in the second eye is the one that is easiest to avoid.
- Where the attack does not settle, or where the angle remains closed, surgery follows. This is decided on the response within hours rather than after a prolonged trial of medication.
The point worth remembering. The damage in an acute attack accumulates over hours, so the timing of presentation is the single most important factor in the outcome. Severe one-sided eye pain with headache, nausea, halos around lights and falling vision is a reason to attend an emergency department rather than to wait for an outpatient appointment.
Follow-up: the part of treatment that makes it work
Glaucoma is a condition managed over decades, and the schedule of checks is not administrative but the mechanism by which control is judged:
- Pressure is measured at each visit, and where it is close to the target, repeated. A single reading is a snapshot; the pattern matters more.
- Fields are repeated at intervals to show whether the loss is stable, and the interval is shorter where damage is advanced or progressing.
- Nerve imaging is repeated to detect thinning sooner than the field would register it, and it is always compared against the person’s own earlier images.
- The treatment plan is revised rather than fixed. A target that was appropriate when damage was mild may be too high once more has been lost, and progression on the tests is the signal to change something.
- Adherence is discussed openly, because an eye whose pressure is rising is more often one where drops are being missed than one where the drug has stopped working.
What is reasonable to expect. With treatment and follow-up, many people with glaucoma keep the field they have for the rest of their lives. The aim of a well-run schedule is that no visit brings a surprise: stability is confirmed, and change is detected while there is still time to respond to it.